title: Clodronate news of efficacy in osteoporosis.
abstract: Clodronate belongs to Bisphosphonates family and it has been studied especially for osteoporosis treatment, Paget's disease, osteolytic metastases, hypercalcemia malignancy and some childhood skeletal diseases. Besides the osteoporosis treatment, it has been successfully used for treating tumoral osteolysis and for bone localization of multiple myeloma, hypercalcemia malignancy, primary hyperparathyroidism, Paget's disease and algodystrophy. Filipponi study showed a statistically significant reduction of the incidence of vertebral fractures after 4 years of treatment with clodronate, intravenously administered at a dose of 200 mg every three weeks. Frediani study, published in 2003 on BONE, proved the clodronate efficacy in the prevention of fractures caused by glucocorticoid-induced osteoporosis (GIO). Clodronate doses of 800 mg/day per os and 100 mg i.m./week are substantially equivalent, because the oral absorption is about 1,9%. A higher efficacy on BMD was documented in various works, especially in cohorts of patients with a greater fracture risk, using higher doses (1600 mg per os). This has led to the hypothesis of using clodronate 200 mg i.m. formulation. Clodronate is an osteoporosis drug that can be assumed in different doses (100 mg i.m./week, clodronate 200 mg i.m. every 2 weeks) considering the risk band, identified by algorithms (FRAX o DeFRA), by BMD and by the presence of at least one risk factor. That means that it is possible to envisage a differentiated use of clodronate adapting the doses to the fracture risk and to the severity of pain symptoms, thus promoting a greater adherence to the therapy. To conclude clodronate is helpful in reducing fracture risk, is safe, well tolerated, and has a good rate cost/effectiveness in patients with fracture risk over 7% established with FRAX.
authors.affiliation: Company ULSS 18, Rovigo, Italy.
authors.forename: Alfredo
authors.initials: A
authors.lastname: Nardi
authors.affiliation: Hospital Carlo Poma, Mantova, Italy.
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Ventura
authors.affiliation: Company ULSS 18, Rovigo, Italy.
authors.forename: Luisella
authors.initials: L
authors.lastname: Cozzi
authors.affiliation: Company ULSS 18, Rovigo, Italy.
authors.forename: Greta
authors.initials: G
authors.lastname: Tonini
keywords: BMD; GIO; adherence; bisphosphonates; clodronate; cost-effectiveness; fracture risk reduction; prevention fractures